Clinical trial · Interventional
Adaptive Radiotherapy in Non-small Cell Lung Cancer (NSCLC)
Adaptive Radiotherapy for Stage II-III Non-small Cell Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators group uses an individualised radiation dose approach in which the dose is escalated up to pre-defined tissue constraints (see below). The target dose to the tumor is 69Gy. However, this dose cannot be reached in approximately 30% of the patients, even with an IMRT (Intensity Modulated Radiotherapy) technique, because the MLD (Mean Lung Dose) constraint of 20Gy is reached at a TTD (Total Treatment Dose) below 69Gy. In this study, the investigators will adapt the treatment by performing a new (PET)-CT at day 12 during radiotherapy and in case of a decreased Planning Target Volume (PTV), the dose mey be increased.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radiotherapy and concurrent chemo-therapy | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Radiotherapy
- interventionNames
- Other: Radiotherapy and concurrent chemo-therapy
Primary outcomes (1)
- measure
- Proportion of patients able to receive 69Gy as TTD
- timeFrame
- 3 months
Secondary outcomes (5)
- measure
- Overall survival
- timeFrame
- 3 months
- measure
- Progression free survival
- timeFrame
- 3 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histological or cytological proven NSCLC * UICC stage I-III, or solitary metastases (\<6), which are amendable for radical local treatment * Performance status 0-2 * IMRT technique Exclusion Criteria: * Not NSCLC of mixed NSCLC and other histologies (e.g. small cell carcinoma) * Stage IV, except for solitary (\<6) metastases * Performance status 3 or more
References
Publications (0)
Data not yet available